CPIX - Cumberland Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.10
-0.09 (-1.73%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close5.19
Open5.17
Bid4.04 x 1000
Ask5.10 x 1300
Day's Range5.04 - 5.18
52 Week Range4.19 - 6.99
Volume29,619
Avg. Volume15,411
Market Cap77.438M
Beta (5Y Monthly)0.14
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • Cumberland Pharmaceuticals Announces The National Launch Of A New Caldolor Ready-To-Use Product
    PR Newswire

    Cumberland Pharmaceuticals Announces The National Launch Of A New Caldolor Ready-To-Use Product

    Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company with a focus on hospital acute care, today announced the launch of Caldolor® (ibuprofen) Injection in a ready-to-use bag that may be administered without dilution for pain relief. This launch follows FDA approval in 2019 of the product's new delivery method.

  • PR Newswire

    Cumberland Pharmaceuticals To Hold Update Call To Discuss Recent Major Developments

    Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will hold an update call to discuss recent developments and plans for the Company's Caldolor® and RediTrexTM brands after the market closes on Tuesday, January 7, 2020. Cumberland will also give 2020 financial guidance during the call. A conference call and live Internet webcast will be held on Tuesday, January 7, at 4:30 p.m. Eastern Time to discuss the results.

  • PR Newswire

    Cumberland Pharmaceuticals Reports 22% Revenue Growth In The Third Quarter

    NASHVILLE, Tenn. , Nov. 12, 2019 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company focused on hospital acute care and gastroenterology today announced ...

  • PR Newswire

    Cumberland Pharmaceuticals To Announce Third Quarter 2019 Financial Results

    NASHVILLE, Tenn. , Nov. 5, 2019 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2019 financial results after the market closes on Tuesday, ...

  • PR Newswire

    New Study Reveals Superiority Of Vibativ® Over Vancomycin In Select Patients With Bacterial Pneumonia

    NASHVILLE, Tenn., Oct. 15, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a U.S. specialty pharmaceutical company announces a new publication in Infectious Diseases and Therapy, showing numerically superior cure rates of telavancin compared to vancomycin within a subset of patients who were enrolled in phase 3 ATTAIN trials and had hospital-acquired pneumonia caused by bacteria with low susceptibility to vancomycin. Cumberland manufactures and distributes telavancin under the brand name Vibativ®. Vibativ® (telavancin) is a patented, FDA approved anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia.

  • PR Newswire

    Cumberland Pharmaceuticals Announces FDA Orphan Drug Grant Award For New Phase II Clinical Program

    NASHVILLE, Tenn., Sept. 24, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a specialty pharmaceutical company, today announced FDA Orphan Drug Grant funding for a new Phase II clinical program. The Company has initiated the clinical development of ifetroban for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD). Based on pre-clinical findings, the U.S. Food and Drug Administration (FDA) has cleared Cumberland's application to study ifetroban in DMD patients, 7 years of age and older.  In addition, Cumberland has been awarded just over $1 million in funding from the FDA through their Orphan Drug Grant program to support a Phase II DMD clinical study.

  • PR Newswire

    Cumberland Pharmaceuticals Reports 14% Revenue Growth In The Second Quarter

    NASHVILLE, Tenn. , Aug. 14, 2019 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company focused on hospital acute care and gastroenterology today announced ...

  • PR Newswire

    Cumberland Pharmaceuticals To Announce Second Quarter 2019 Financial Results

    NASHVILLE, Tenn. , Aug. 7, 2019 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2019 financial results after the market closes on Wednesday, ...

  • PR Newswire

    Cumberland Pharmaceuticals Signs Exclusive Licensing Agreement For Distribution In China

    NASHVILLE, Tenn., May 15, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a specialty pharmaceutical company, today announced it has entered into an exclusive agreement with China's Winhealth Pharma Group for the licensing rights of Acetadote®  (acetylcysteine) Injection, used to prevent or reduce liver damage resulting from acetaminophen overdose, and Caldolor®  (ibuprofen) Injection, which is used to treat pain and fever in the hospital setting. The agreement will provide Winhealth licensing rights to commercialize both FDA approved drugs in China, the second largest market for pharmaceuticals in the world after the U.S. There have been patents issued for both brands in China.

  • PR Newswire

    Cumberland Pharmaceuticals Reports 38% Revenue Growth In The First Quarter

    NASHVILLE, Tenn. , May 14, 2019 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive ...

  • PR Newswire

    Cumberland Pharmaceuticals To Announce First Quarter 2019 Financial Results

    NASHVILLE, Tenn. , May 7, 2019 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2019 financial results after the market closes on Tuesday, ...

  • PR Newswire

    Cumberland Pharmaceuticals Announces Strategic Review

    NASHVILLE, Tenn., March 29, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a specialty pharmaceutical company, today announced that it has commenced a strategic review of its branded product portfolio, as well as its roster of international partners. The Company expects to communicate results from the review during its upcoming report on the first quarter of 2019. Following the Company's acquisition of Vibativ® in late 2018, its commercial portfolio now includes eight FDA-approved brands.

  • PR Newswire

    Cumberland Pharmaceuticals Reports Fourth Quarter Revenue Growth Of 16%

    - Acquired Vibativ® from Theravance Biopharma - Closed largest product transaction in Company's history - Acquisition funded by $20 million credit line expansion NASHVILLE, Tenn. , Feb. 26, 2019 /PRNewswire/ ...

  • ACCESSWIRE

    Cumberland Pharmaceuticals Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 26, 2019 / Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 26, ...

  • PR Newswire

    Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2018 Financial Results

    NASHVILLE, Tenn. , Feb. 19, 2019 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2018 financial results after the market closes ...